Roche Invests $750m to Double US Manufacturing Plant

Roche has barely finished celebrating one American milestone before announcing another.

Days after the Swiss pharmaceutical group marked topping out on its US$2bn manufacturing complex in Holly Springs, North Carolina, it confirmed a fresh US$750m commitment to roughly double the footprint of its established plant in Hillsboro, Oregon.

Genentech, Roche's US biotechnology subsidiary, will run both sites, reinforcing the group's determination to expand domestic drug production at pace.

For an industry racing to secure cleanroom capacity, skilled labour and specialist contractors, the announcement adds another major project to an already crowded pipeline of pharmaceutical construction work across the country.

Roche ranks as the world's fifth-largest pharmaceutical company by revenue and holds the top global position in cancer care.

The business employs more than 112,000 people worldwide and reported annual revenue of approximately CHF62bn (US$77.5bn).

In the US, Roche already runs 13 manufacturing plants and 15 research and development sites, supporting close to 25,000 employees across 24 locations in eight states.

Genentech CEO Ashley Magargee frames the Hillsboro announcement as a natural extension of the company's long history in the state.

"We are proud to make this significant new investment in Hillsboro, building on nearly two decades of Genentech manufacturing in Oregon," she says.

"By adding end-to-end filling capabilities, this expansion deepens our commitment to manufacturing in the US and gives us the flexibility to support a growing pipeline."

Established site set for upgrade

Hillsboro has operated since 2006 and has become one of the most important nodes in Genentech's American manufacturing network, turning out treatments spanning oncology, immunology and neurology.

The planned expansion will bring device-filling capability onto the site for the first time, adding a capacity the facility has previously lacked and strengthening the broader domestic supply chain for complex biologic medicines.

Because Hillsboro already has established utilities, qualified staff and two decades of regulatory and operational history behind it, the expansion is arguably a lower-risk build than a greenfield campus.

For contractors, that combination of existing infrastructure and an experienced local workforce should translate into a faster path from groundbreaking to validated production, provided labour and materials can be secured on schedule.

Roche has also cultivated close relationships with Oregon state and community partners over the life of the site — relationships likely to smooth permitting and site logistics as work gets underway.

Part of a wider US pledge

The Hillsboro and Holly Springs projects sit within a much larger commitment.

Holly Springs itself has grown substantially since it was first announced, with planned investment rising from an initial $700m to $2bn. Both expansions are part of the $50bn Roche pledged in April 2026 to support US manufacturing infrastructure over five years.

Roche Group CEO Thomas Schinecker described the pledge's scale at the time. "[These] investments underscore our long-standing commitment to research, development and manufacturing in the US," he said.

"We are proud of our 110-year legacy in the United States, which has been a key driver for jobs, innovation and the creation of intellectual property in the US... Our investments of $50bn over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world."

Roche is far from alone

Roche's spending sits within a much wider surge of pharmaceutical reshoring across the United States, a trend accelerated by the threat of tariffs on medicines manufactured overseas under President Donald Trump.

Rival drugmakers have announced comparably enormous sums in recent months.

Novartis has committed $23bn to building or expanding ten US facilities. Johnson & Johnson has pledged $55bn toward domestic manufacturing, including three entirely new sites, while Eli Lilly is midway through a $27bn investment programme covering four additional plants.

Bristol Myers Squibb has made a similar move, unveiling a $2.3bn "multi-modal manufacturing campus" in Houston, Texas, as part of a broader $40bn, five-year plan covering US research, technology and manufacturing.

"This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation," said BMS Board Chair and CEO Christopher Boerner.

"As part of our $40bn commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life."

A boom construction firms feel

For construction executives, this run of nine- and ten-figure pharmaceutical announcements represents one of the busiest periods the sector has seen in decades.

Pharmaceutical companies are collectively planning more than $370bn in US manufacturing investment over the next five years, a wave of demand that is straining the construction labour market at a time when the industry needs hundreds of thousands of additional workers to keep projects on schedule.

Firms with proven experience in cleanroom construction, sterile-environment fit-out and biologics facilities stand to benefit most, but they will also face the sharpest competition for the specialist tradespeople this scale of work demands.